23 Participants Needed

sEphB4-HSA for Kaposi Sarcoma

Recruiting at 10 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: AIDS Malignancy Consortium
Must be taking: Antiretrovirals
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.

Who Is on the Research Team?

IW

Ida Wong-Sefidan

Principal Investigator

AIDS Malignancy Consortium

Are You a Good Fit for This Trial?

This trial is for individuals with Kaposi Sarcoma, which may include those who haven't been treated before or those who didn't respond to or couldn't tolerate previous treatments. HIV-positive participants are welcome if they're on stable antiretroviral therapy. Participants need a life expectancy over 3 months and must have skin lesions suitable for biopsy. They should not be pregnant and must agree to use effective birth control methods.

Inclusion Criteria

You are expected to live for more than 3 months.
Participants must, in the opinion of the investigator, be capable of complying with the protocol
I have Kaposi's sarcoma confirmed by a biopsy, affecting my skin and possibly other organs.
See 15 more

Exclusion Criteria

Participants who are receiving any other investigational agents
I do not have severe diabetes, COPD requiring recent hospitalization, or conditions that make treatment risky for me.
I have not had a serious infection or been treated for one in the last 14 days.
See 26 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses may receive treatment on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses.

Up to 12 months
2 visits per course, up to 4 visits per course if escalated

Follow-up

Participants are monitored for safety and effectiveness after treatment completion. Patients with partial response or better are followed up every 3 months for up to 1 year.

12 months
Every 3 months

What Are the Treatments Tested in This Trial?

Interventions

  • Recombinant EphB4-HSA Fusion Protein
Trial Overview The study is testing the effects of recombinant EphB4-HSA fusion protein on Kaposi Sarcoma. This treatment aims to block blood vessel growth that feeds cancer cells and prevent the cancer cells from growing further.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Treatment (recombinant EphB4-HSA fusion protein)Experimental Treatment4 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

AIDS Malignancy Consortium

Lead Sponsor

Trials
64
Recruited
9,600+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Vasgene Therapeutics, Inc

Industry Sponsor

Trials
9
Recruited
1,000+

The Emmes Company, LLC

Industry Sponsor

Trials
149
Recruited
1,052,000+
Peter Ronco profile image

Peter Ronco

The Emmes Company, LLC

Chief Executive Officer since 2023

BSc from Nottingham University

Dr. Joe Sliman profile image

Dr. Joe Sliman

The Emmes Company, LLC

Chief Medical Officer since 2020

MD from Uniformed Services University of the Health Sciences, MPH from Johns Hopkins University, BSc in Molecular and Cell Biology from Pennsylvania State University

University of Arkansas

Collaborator

Trials
500
Recruited
153,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security